Under Pressure: Can Merck Show Cubist Is Worth $9.5 Billion Without Cubicin?

Hours after Merck revealed a merger agreement with Cubist, a court ruled that generic versions of Cubist’s big seller Cubicin can launch in 2016, two years earlier than expected, putting the pressure on Merck to justify the pricey acquisition.